Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma

#4364

Introduction: Radiolabelled therapy with meta-iodobenzguanine (MIBG) and chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine can help manage patients with metastatic pheochromocytoma and paraganglioma (mPPGL). The phase II FIRSTMAPPP study supports the use of the tyrosine kinase inhibitor sunitinib in these malignancies, with median progression-free survival values of 8.9 versus 3.6 months and overall response rates of 31% versus 8% for sunitinib versus placebo. The median duration of sunitinib therapy was 11 months. Concurrent with this study, we launched a single-arm trial to examine the activity of a similar tyrosine kinase inhibitor, axitinib.

Aim(s): Axitinib efficacy.

Materials and methods: Axitinib was self-administered at a dose of 5 mg every 12 hours continuously in a 28-day cycle. All patients were evaluated for dose adjustments to levels of 2, 3, 7, and 10 mg bid, with intervals of at least 4 weeks between any dose escalations. Efficacy evaluations using conventional imaging were performed every 12 weeks.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Fojo T, Edgerly M, Pacak K, Figg W,

Keywords: PPGL, pheochromocytoma, paraganglioma, axitinib, TKI, tyrosinase kinase inhibitors,